• Epinephrine Bitartrate: From Receptor to Assay

  2026-08-11

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist with applications spanning vascular, cardiac, respiratory, and neurobiology research. This article presents a receptor-to-phenotype framework and explains why clinical vasopressor conversion data should inform, not dictate, laboratory assay design.

• SB 202190 in CRC Organoid Immunology

  2026-08-11

  A translational framework for using SB 202190 as a mechanistic probe in colorectal cancer organoid–T cell models, connecting p38α/p38β signaling with tumor-induced Treg differentiation, inflammation research, apoptosis assays, and biomarker strategy.

• SB-3CT: From MMP9 Biology to Better ECM Assays

  2026-08-10

  SB-3CT is a selective gelatinase inhibitor for dissecting MMP-2 and MMP-9 activity across extracellular matrix models. This article translates new Adamtsl3–MMP9 findings into more rigorous assay strategies while distinguishing demonstrated neurobiology from future SB-3CT applications.

• Nipah Virus Polymerase Complex: Structural Insights

  2026-08-09

  The reference preprint presents cryo-EM and X-ray structures of the Nipah virus L-P polymerase machinery, resolving how the catalytic L protein and tetrameric P protein assemble. The structures define polymerase-domain organization and identify magnesium coordination in the connecting domain, providing a mechanistic framework for Nipah antiviral discovery while leaving inhibitor validation for future work.

• Tacalcitol Monohydrate: Applied Research Workflows

  2026-08-08

  Tacalcitol monohydrate connects VDR-driven gene regulation with practical workflows in keratinocyte, NGF, and colorectal cancer models. This guide shows how to prepare, dose, combine, and troubleshoot the compound for psoriasis-related research and 5-fluorouracil sensitization studies.

• (S)-(+)-Ibuprofen: COX Inhibitor Guide

  2026-08-07

  (S)-(+)-Ibuprofen is the pharmacologically active ibuprofen enantiomer and a useful COX inhibitor for inflammation pathway research. Its reported in vitro COX-2 and COX-1 IC50 values are 1.9 μM and 2.5 μM, respectively, but assay conditions and translational limits must be documented.

• Danazol (SKU C3644): Reproducible Endocrine Assays & Lab Str

  2026-08-07

  This article provides scenario-driven, evidence-based guidance for using Danazol (SKU C3644) in cell viability, proliferation, and endocrine modeling workflows. It highlights reproducibility, protocol optimization, and vendor selection considerations, ensuring robust data for biomedical researchers. Explore why APExBIO’s Danazol is a preferred standard for reliable inhibition of steroidogenesis and hormone axis studies.

• Risedronate Sodium: Mechanistic Leverage for Translational A

  2026-08-06

  This thought-leadership article decodes the mechanistic and translational landscape of Risedronate Sodium, spotlighting its role as a farnesyl pyrophosphate synthase inhibitor in bone, lung, and cancer research. Drawing on recent innovations in nano-delivery and transdermal technologies, we provide actionable guidance and protocol insights for researchers aiming to bridge preclinical discoveries with clinical impact. With new evidence on formulation strategies and cross-domain applications, this piece elevates the conversation beyond standard product summaries, positioning APExBIO’s Risedronate Sodium as a strategic tool in next-generation translational workflows.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A

  2026-08-06

  Temafloxacin, a potent fluoroquinolone broad-spectrum antibacterial agent from APExBIO, excels in both in vitro and in vivo models for Gram-positive, Gram-negative, and intracellular pathogen research. This article reveals streamlined workflows, troubleshooting strategies, and the unique strengths of Temafloxacin validated by comparative studies.

• Risedronate Sodium: FPP Synthase Inhibitor in Bone Research

  2026-08-05

  Risedronate Sodium’s inhibition of farnesyl pyrophosphate synthase uniquely positions it for advanced bone metabolism and cancer research. Here, we decode experimental workflows, highlight troubleshooting strategies, and translate key findings—empowering labs to harness its full translational and preclinical value.

• WAY-100635: Advancing 5-HT1A Antagonist Research in Pain Mod

  2026-08-05

  WAY-100635 stands as a gold-standard 5-HT1A receptor antagonist for dissecting serotonergic mechanisms in pain and affective neuroscience. This article translates recent breakthroughs—especially in multidimensional pain models—into actionable protocols, troubleshooting insights, and advanced assay strategies for applied receptor pharmacology.

• Parathyroid hormone (1-34) (human): Precision in Bone and Ki

  2026-08-04

  Parathyroid hormone (1-34) (human) empowers high-fidelity modeling of bone metabolism and CKD-related vascular calcification through potent PTH/PTHrP receptor signaling. With quantifiable performance and adaptive workflow versatility, this APExBIO reagent bridges mechanistic insight and applied research in osteoporosis, serum calcium regulation, and beyond.

• MRTFA-KCNMB1 Axis: Ionic Regulation of Cancer Cell Stiffness

  2026-08-04

  Gajda et al. uncover how the MRTFA-KCNMB1 axis modulates cancer cell stiffness via potassium channel regulation, linking biomechanical properties to metastatic potential and immune evasion. Their integrated genetic and pharmacological approach highlights ionic signaling as a therapeutically actionable pathway for altering tumor cell mechanics and improving immunogenic clearance.

• Tacalcitol Monohydrate: Synthetic Vitamin D3 for Translation

  2026-08-03

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, unlocks advanced workflows in dermatology and oncology by precisely modulating VDR and CaSR pathways. Its robust induction of NGF and synergy with 5-fluorouracil set it apart for both mechanistic and translational research, while low calcemic toxicity expands its experimental scope.

• Berberrubine Inhibits Thrombosis via Vitamin K Cycle Modulat

  2026-08-03

  This study demonstrates that berberrubine, a metabolite of berberine, inhibits thrombosis in mice by targeting the vitamin K catalytic cycle, without increasing bleeding risk. Integrated metabolomics and molecular docking approaches revealed its action on key enzymes, suggesting new avenues for safer antithrombotic drug development.

16438 records 1/1096 page Next 12345 下5页 Last page